Report | Question ID | Question | Discussion | Answer | Year |
---|---|---|---|---|---|
|
20041016 | CS Site Specific Factor 4--Prostate: If PAP is not mentioned in the chart, should Site Specific Factor 4 be coded to 999 [unknown or no information] or 000 [test not done]? | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.For tumors diagnosed 2004 only:
Code the CS Site Specific Factor 4 to 999 [Unknown or no information; Not documented in patient record]. If there is no report of a lab test in the health record, code as 999.
Code this field to 000 [Test not done] when there is a statement in the record that a test was not performed.
Tumors diagnosed 1/1/2005 forward no longer have PAP coded in the Site Specific Factor 4 field. |
2004 | |
|
20041080 | Behavior Code/CS Extension--Brain and CNS: How are these fields coded when the final diagnosis on pathology indicates that an atypical meningioma invades the brain and the bone flap specimen indicates extensive invasion through the full thickness of the calvarium? See Discussion. |
FDx on the path is: A. Rt frontotemporal brain tumor: Atypical meningioma, WHO grade II (out of III). B. Arachnoid tissue: Atypical meningioma with small focus of invasion into superficial brain and focal perivascular spread. C. Bone flap: Atypical meningioma with extensive invasion through full thickness of the calvarium. Comment: Although this tumor shows a small focus of brain invasion, it should be considered a grade II (out of III) meningioma based on its histologic atypia (cellularity, sheeting of tumor cells and prominent nucleoli), elevated Ki-67 index and low mitotic rate. |
This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.For tumors diagnosed prior to 2004, the example above is a benign meningioma and not reportable to SEER. For tumors diagnosed 2004 or later, code the behavior as 1 [Borderline malignancy]. Code CS Extension as 05 [Benign or borderline brain tumors]. According to expert consultant, meningiomas are in the lining cells for the inner table of the skull and as such have an affinity for bone that allows them to penetrate adjacent bone without being "malignant. |
2004 |
|
20071067 | CS Extension/Histology (Pre-2007)--Bladder: Is the histology coded to 8010/2 [carcinoma in situ] or to 8130/2 [papillary transitional cell carcinoma, non-invasive] for a 2006 bladder tumor with a final path diagnosis of "mixed non-invasive papillary TCC and flat carcinoma in-situ" and is CS Extension coded to 01 [Papillary transitional cell carcinoma state to be noninvasive]or to 06 [Carcinoma in situ]? See Discussion. | If the correct code for histology is 8130/2 and CS Extension is 06, this combination does not pass NAACCR edits. | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.For tumors diagnosed prior to 2007, code CS Extension to 06 and histology to 8130/2. Override the NAACCR edit.
For cases diagnosed 2007-2014, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
2007 |
|
20081094 | CS Lymph Nodes--Breast: Now that code 50 [fixed/matted ipsilateral axillary LNS, NOS] is obsolete, how is this field coded for a case in which there are clinically matted lymph nodes, no neoadjuvant therapy, and no lymph node size on the available pathology report? | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.From the American College of Surgeons: The pathologic information always takes precedence over the clinical information when there is no neoadjuvant therapy. The size reference is that this is not ITC or micromets. Clinically, I don't think you can have fixed or matted nodes that aren't greater than micromets. This would be coded to 52. The mapping for all of these codes is not taken from this, but from the value of SSF3 per the note at the bottom of the table. See CS Lymph Nodes note 2. |
2008 | |
|
20091063 | CS Lymph Nodes--Head and Neck: How is this field coded when a positive neck FNA is followed by a neck dissection that contains one of seventeen positive lymph nodes? See Discussion. | The primary site is the right tongue. The patient underwent FNA of a right neck mass that was positive for squamous cell carcinoma. Subsequent right modified radical neck dissection showed one out of seventeen nodes positive for metastatic carcinoma. For head and neck primaries, the CS LN codes 10-19 represent a single positive ipsilateral regional node. Codes 20-29 represent multiple positive ipsilateral nodes. | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.If the neck dissection included the area of the positive FNA, count only the positive nodes from the dissection. Avoid double-counting a positive node for both an FNA and a dissection. In the unlikely event that the dissection did not include the area of the positive FNA, add one positive node to the count from the dissection. This instruction supersedes previous instructions. |
2009 |
|
20041075 | CS Tumor Size: Can we take the size of a "polypoid" mass? See Discussion. | 3/04 Colonoscopy: 4 cm semi-circumferential friable mass in sigmoid colon. Path: Tubulovillous adenoma indeterminate for malignancy. 4/04 Sigmoid Colectomy: 5 x 4 polypoid mass: WD Adenocarcinoma arising in a tubulovillous adenoma. Define "Polypoid". Size of "polypoid" mass. Would the size be coded to 050 or 999? |
This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.If the pathology report confirms that the entire polyp is malignant, code the size of the polyp/polypoid mass. If the pathology report does not confirm that the entire polyp is malignant, code 999. Code tumor size as 999 [Unknown] for the example above. Do not code the size of the polypoid mass in this example. The size given above is the size of the polypoid mass, not the size of the malignancy. Polypoid means "Like a polyp. |
2004 |
|
20061101 | CS Site Specific Factor--Colon: If the patient has a polypectomy followed by definitive surgery, can a higher CEA reported after the polypectomy but before the colon resection be coded? | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.If the tumor was in the polyp, do not use the post-polypectomy CEA even if it is higher than CEA's prior to the polypectomy. In this situation, the polypectomy would be treatment. Conversely, if this is a frank adenocarcinoma or the tumor was so invasive that the polyp removed only a portion, use the post-polypectomy CEA because the polypectomy would not be treatment in this situation. |
2006 | |
|
20051061 | CS Tumor Size/CS Extension/CS Lymph Nodes--Lung: How are these fields coded when there is no description of a primary lung tumor, lymph node biopsies are negative, but biopsy of a "level 7 mass" is positive for squamous cell carcinoma? See Discussion. | Example: Chest CT: Enlarging subcarinal mass, 3.4 cm, is most likely malignant adenopathy or perhaps primary tumor. The clinician subsequently described a patient history of mediastinal lymphadenopathy. He stated that a PET scan revealed multifocal thoracic disease consistent with stage 3B carcinoma. This was followed by mediastinoscopy with lymph node biopsies (all negative) but the biopsies of "level 7 mass and subcarinal level 7 mass" showed squamous cell carcinoma. | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.If this case is determined to be a lung primary, code the CS fields: CS Tumor Size: 999 [Unknown] CS Extension: 99 [Primary tumor cannot be assessed] CS Lymph Nodes: 20 [Subcarinal lymph node involvement] based on positive level 7 biopsy, history of mediastinal lymphadenopathy and subcarinal "adenopathy" per CT. |
2005 |
|
20071058 | CS Tumor Size: Is a measured "area" equivalent to a tumor, mass or lesion size? See Discussion. |
Collaborative Stage manual, page 26 Rule 4a: "always code size of the primary tumor, not size of the polyp, ulcer, cyst or distant metastasis." Rule 4e: Additional rule for breast primaries: Example: Duct carcinoma in situ covering a 1.9 cm area with focal areas of invasive ductal carcinoma. Record the tumor size as 1.9 cm. |
This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.In general, a measured area is not equivalent to a tumor size. Do not apply the rule related to the breast example to other primary sites. This example in the CS manual pertains to coding tumor size for breast primaries when the size of the invasive component is not stated. In the example, the area involved with duct carcinoma in situ is the only measurement available. The size of the invasive component was not given. |
2007 |
|
20091036 | CS Mets at DX/CS Extension--Ovary: Is carcinomatosis always captured in the CS Mets field? Can the term carcinomatosis be used to describe peritoneal implants as well? See Discussion. | 1/18/06 CT guided biopsy of abdominal mass & ant peritoneum nodule: Extensive carcinomatosis affecting the paracolic gutters, liver surface & pelvis. 6 cm tumor mass was visibly engulfing the small bowel & tube; poorly differentiated adenoca, mullerian derived, shows attributes of clear cell carcinoma, high grade (FIGO III), 2.5 cm size, does not involve fallopian tube. R&L abdominal wall & mesentery, mets adenoca. 5/31/06: tumor debulking with right salpingo-oophorectomy. Final DX: Poorly differentiated adenocarcinoma, clear cell type, right ovary (FIGO III), stage IV per MD. |
This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.In the case of ovarian cancer, the term carcinomatosis may refer to peritoneal implants, especially when the implants are numerous. It does not refer to distant metastases in this context. This issue has been forwarded to the CS version 2 committee. |
2009 |